Ganciclovir Injection, Powder, Lyophilized, For Solution
Product Images NDC 0143-9299

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ganciclovir (NDC 0143-9299). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ganciclovir Sodium Structural Formula (Ganciclovir For Injection Usp 1)

Chemical structure of Ganciclovir sodium, showing the molecular arrangement of atoms and bonds characteristic of this antiviral agent.*

FDA Label Image

Ganciclovir Structural Formula (Ganciclovir For Injection Usp 2)

Chemical structure diagram of ganciclovir sodium, showing its molecular arrangement with nitrogen, oxygen, carbon, and hydrogen atoms connected in the characteristic guanine derivative and side chain.*

FDA Label Image

Figure 1 (Ganciclovir For Injection Usp 3)

A line graph titled 'ICM 1653: Time to Progression of CMV Retinitis' depicting the proportion without progression over time from the start of maintenance therapy in days. Two lines compare intravenous (IV) and oral routes, showing decreasing proportions over approximately 150 days.*

FDA Label Image

Figure 2 (Ganciclovir For Injection Usp 4)

A line graph titled 'ICM 1774: Time to Progression of CMV Retinitis' showing the proportion without progression over time in days since the start of maintenance therapy. Two curves compare intravenous (IV) and oral routes. The Y-axis represents the proportion without progression from 0 to 1, and the X-axis shows time up to 120 days.*

FDA Label Image

Figure 3 (Ganciclovir For Injection Usp 5)

A line graph titled 'AVI 034: Time to Progression of CMV Retinitis,' showing the proportion of patients without progression over time from the start of maintenance therapy (days). It compares two treatment routes, intravenous (IV) and oral, with IV represented by a dashed line and oral by a solid line.*

FDA Label Image

Ganciclovir For Injection, Usp 500 mg Per Vial Container Label (Ganciclovir For Injection Usp 6)

Label for Ganciclovir injection, USP 500 mg per vial, lyophilized powder for intravenous infusion. The product is manufactured by Thymoorgan Pharmazie GmbH, Germany and distributed by Hikma Pharmaceuticals USA Inc. Dosage instructions, storage temperatures, and a warning about the drug's cytotoxic and carcinogenic potential are included. The NDC is 0143-9299-01.*

FDA Label Image

Ganciclovir For Injection, Usp 500 mg Per Vial Carton Labeling (Ganciclovir For Injection Usp 7)

Ganciclovir for Injection, USP 500 mg per vial powder for lyophilized intravenous injection. The carton includes warnings about the drug being a potent cytotoxic agent and cautions for intravenous infusion only. Labeler is Hikma Pharmaceuticals USA Inc. The package contains 10 single-dose vials.*

FDA Label Image

Representative Serialization Image (Ganciclovir For Injection Usp 8)

The image shows a label featuring a QR code alongside printed text with identifiers including GTIN, serial number (SN), expiration date (EXP), and lot number (LOT). The label is likely affixed to a pharmaceutical product container, but no specific drug name or strength is visible on this label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.